Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2002 | 09-2002 | 06-2002 | 03-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,240 | -24,270 | -16,050 | -7,530 | -32,500 |
| Depreciation Amortization | 4,180 | 3,110 | 2,030 | 960 | 3,470 |
| Other Working Capital | 2,340 | 1,830 | 1,590 | 210 | -5,770 |
| Other Operating Activity | -12,730 | -1,340 | -1,120 | -560 | 1,820 |
| Operating Cash Flow | $-28,450 | $-20,670 | $-13,550 | $-6,920 | $-32,980 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -130 | -130 | -950 | -60 | -650 |
| Other Investing Activity | 26,650 | 22,540 | 15,130 | 3,960 | -16,400 |
| Investing Cash Flow | $26,520 | $22,410 | $14,180 | $3,900 | $-17,050 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 350 | 810 | -360 | -240 | 5,150 |
| Financing Cash Flow | $350 | $810 | $-360 | $-240 | $5,150 |
| Exchange Rate Effect | 470 | 320 | 360 | -70 | 5 |
| Beginning Cash Position | 10,450 | 10,450 | 10,450 | 10,450 | 55,330 |
| End Cash Position | 9,350 | 13,340 | 11,080 | 7,120 | 10,450 |
| Net Cash Flow | $-1,100 | $2,880 | $630 | $-3,320 | $-44,870 |
| Free Cash Flow | |||||
| Operating Cash Flow | -28,450 | -20,670 | -13,550 | -6,920 | -32,980 |
| Free Cash Flow | -28,450 | -20,670 | -13,550 | -6,920 | -32,980 |